Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cardiol Therapeutics Inc T.CRDL

Alternate Symbol(s):  CRDL | T.CRDL.W.A

Cardiol Therapeutics Inc. (Cardiol) is a Canada-based clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.


TSX:CRDL - Post by User

Comment by Youhillmanon Oct 01, 2020 9:33am
129 Views
Post# 31647982

RE:Cortalex Trademark application

RE:Cortalex Trademark application

Interesting to note, this was filed August 15th, the application states it will take 3 months before it's reviewed by an examining Attorney so that means we could be looking at mid to late November before sales commence at Shoppers. 

Does anyone have any information as to why they made the name change for sales at Shoppers's from Cardiolrx to Cortalex? 

As I've stated before, based on Elsley's last 2 presentations, sales at Shoppers has dropped in terms of priority over the use for Covid, which makes sense as it's a much bigger opportunity.

<< Previous
Bullboard Posts
Next >>